Top Menu

The Future of Big Pharma

There are many reasons one can cite to predict big trouble for the drug companies in the next decade and beyond. The most significant is cost control and the expectation that government and private payers will squeeze drug company margins through price controls and less patent protection. Second is the trend towards regulatory conservatism requiring […]

Continue Reading

Bob Ehrlich’s blog on blogs – August 19, 2008

John Mack in his Pharma Marketing Blog of 8/14 wrote an interesting piece called Rethinking the Value of DTC Advertising . Mack says that the numbers of patients who visit and ask doctors about advertised drugs is very low. Therefore, he wonders how the expenditures can pay back on this low a number of patient […]

Continue Reading

Bob Ehrlich's blog on blogs – July 29, 2008

Cliff Mintz in BioJobBlog (July 12) says pharma has discovered You Tube in a big way. He says many drug companies are using it to post ads, educational videos and creating contests for consumers to create videos on what it is like to have certain diseases. He singles out J&J saying “these pharma assaults on […]

Continue Reading

blogspectives June 16, 2008

Ed Silverman in Pharmalot (June 11) comments on the FDA’s report that the biggest reporter of adverse events is now the consumer, not the doctor. In 2007, consumers reported 174,000 events versus only 121,000 from doctors. My take is that part of the reason consumers report more adverse events is familiarity with the side effects […]

Continue Reading

blogspectives – June 2, 2008

Welcome to our first issue of Blogspectives. Bi-weekly I will comment on health blogs that discuss pharmaceutical marketing, public policy, and consumer trends and behavior. This is not a blog recap per se, but my editorial spin, comment, rebuttal or agreement with those bloggers. I scan what I believe are relevant blogs to the DTC […]

Continue Reading